A review by the U.S. Food and Drug Administration (FDA) has found that the AstraZeneca Plc’s diabetes drug, Onglyza, may be associated with an increased rate of death. A trial was underway of more than 16,000 patients taking Onglyza. It has been reported that these patients had an increased risk of hospital visits due to heart failure. The personal injury attorneys at Williams DeClark Tuschman will continue to monitor this as more news unfolds. In the mean time, should you have any questions regarding Onglyza, please call our office at 419-719-5195. We are more than happy to answer any questions you have.
We Are In The Business Of Healing
Diabetes Drug May Be Linked With An Increased Rate of Death
| May 4, 2015 | Firm News
Recent Posts
- Serious crashes can happen when someone runs a red light
- Commercial vehicle accidents often lead to serious injuries
- What serious injuries are common after a motor vehicle crash?
- Pedestrian accidents can leave you with serious injuries
- Dealing with difficult insurance issues in a personal injury claim
Categories
- Auto Recalls
- Bad Faith Insurance
- Bicycle Accidents
- Birth Injuries
- Boating Accidents
- Brain Injury
- Bus Accidents
- Car Accidents
- Catastrophic Injuries
- Child Safety
- Construction Zone Accidents
- Defective Medical Devices
- Drug Safety
- Electric Scooter Injuries
- Firm News
- Health & Safety
- Mass Torts
- Medical Malpractice
- Motor Vehicle Accidents
- Motorcycle Accidents
- Nursing Home Abuse
- Personal Injury
- Premises Liability
- Product Liability
- Sex Trafficking
- Sports Injury
- Truck Accident
- Wrongful Death